Abstract: A p16INK4a inhibitor, a composition that includes the p16INK4a inhibitor, or a pharmaceutical composition that includes the p16INK4a inhibitor, for use in the prevention and/or the treatment of Huntington's disease, wherein the p16INK4a inhibitor is a nucleic acid or a peptide, a small compound molecule or a marketed drug.

Abstract: The present invention relates to the prediction of the age-at-onset of Huntington's disease. More specifically, it relates to the use of at least one FoxO-centered network related biallelic markers, preferably single nucleotide polymorphism (SNP) markers, in particular GSK-3? and/or TCERG1 and/or FOXO1 and/or FZD10 related biallelic markers, for prognosing the age-at-onset of symptoms of Huntington's disease in an individual at risk of suffering from said disease.

Abstract: A system for supplying at least one electrical apparatus with a touch control. The system may be utilized in a home automation system for supplying electrical equipment, e.g., light bulbs, motors, strip lights, electrical power points, etc., or may be utilized to form part of equipment, e.g., a lamp, lamp stand, etc. The system may include treated zones formed by chemical treatment of an electrically insulating support material to provide the zones with a reduced electrical impedance to allow leakage current flow. The treated zones may be electrically coupled to a detection input of an electrical control circuit to allow the leakage current to be detected by the detection input and enable the electrical control circuit to control a switch in accordance with the leakage currents, which are generated in the treated zone when a user touches the treated zone.